ArticleCancer medicine2016
Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score.
Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Multicentre Evaluation of an AI-Assisted Urine Test for Clinically Significant Prostate Cancer in Men Undergoing Initial Biopsy.Journal of extracellular vesicles · 2026Article
- Deep Sequencing Reveals Novel Mutations inInternational journal of molecular sciences · 2025Article
- Trends in Prostate Cancer Incidence and Survival by Gleason Score from 2000 to 2020: A Population-Based Study in Northeastern Italy.Current oncology (Toronto, Ont.) · 2025Article
- Exploring the Epidemiological Characteristics and Survival Analysis Among Prostate Cancer Patients Under 50: A Seer-Based Population Study.Health science reports · 2025Article
- Discovery of Essential Genes as Possible Targets for Prostate Cancer Drug Development.International journal of genomics · 2025Article
- Putting patients first to redefine prostate cancer classifications.Journal of the National Cancer Institute · 2023Article
- Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies.British journal of cancer · 2023Article
- Understanding the Role of Urology Practice Organization and Racial Composition in Prostate Cancer Treatment Disparities.JCO oncology practice · 2023Article
- Article
- Prediction of surgical margin status and location after radical prostatectomy using positive biopsy sites on 12-core standard prostate biopsy.Scientific reports · 2022Article
- Understanding Active Surveillance for Prostate Cancer.JCO oncology practice · 2021Article
- Urology Workforce Changes and Implications for Prostate Cancer Care Among Medicare Enrollees.Urology · 2021Article
- Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials.World journal of urology · 2021Review
- Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.European urology focus · 2021Article
- High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up.Frontiers in oncology · 2021Article
- A TMPRSS2-ERG gene signature predicts prognosis of patients with prostate adenocarcinoma.Clinical and translational medicine · 2020Article
- High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses - 14 years of single-centre experience.Journal of contemporary brachytherapy · 2020Article
- Management of prostate cancer patients during COVID-19 pandemic.Prostate cancer and prostatic diseases · 2020Review
- Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.World journal of urology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Prostate cancer incidence is sensitive to screening practices, however the impact of recent screening recommendations from the United States Preventative Services Task Force on prostate cancer incidence by age, stage, race, and Gleason score is unknown. This study described the timing and magnitude of changes in prostate cancer incidence trends in the United States by month of diagnosis, and evaluated trends by age, Gleason score, and stage at diagnosis. We analyzed prostate cancer incidence trends using Surveillance, Epidemiology, and End Results (SEER) program data for men diagnosed with invasive prostate cancer from 2007 through 2012. JoinPoint analysis was used to detect changes in the rate of annual percent change (APC) in prostate cancer incidence for all diagnoses and by age, Gleason score, race, and stage. Prostate cancer incidence declined at an estimated -19.6% APC beginning May 2011. This decline was observed in all age groups. Low-grade tumors (Gleason score ≤6) showed a steeper decline (-29.1% APC) than high-grade tumors (Gleason score 8-10: -10.8% APC). Only stage I/II and stage III tumors saw declines (-24.2% and -16.7% APC, respectively). A sharp decline in prostate cancer incidence began before release of the United States Preventative Services Task Force October 2011 draft and May 2012 final screening recommendation. The greatest change occurred with incidence of low-grade tumors, although there is concern that some high-grade tumors may now go undetected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.